MET Amplification

7 registered clinical trials studyying MET Amplification — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification NCT07322783	Qingdao Central Hospital	Phase 2
Recruiting	The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558	Hunan Province Tumor Hospital	Phase 1 / Phase 2
Recruiting	Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC NCT05800340	Guangdong Provincial People's Hospital	Phase 2
Unknown	Lorlatinib Combinations in Lung Cancer NCT04292119	Massachusetts General Hospital	Phase 1 / Phase 2
Unknown	Tepotinib in Solid Tumors Harboring MET Alterations NCT04647838	Chungbuk National University Hospital	Phase 2
Recruiting	Study of Crizotinib for ROS1 and MET Activated Lung Cancer NCT04084717	University Health Network, Toronto	Phase 2
Recruiting	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid NCT03175224	Apollomics Inc.	Phase 2